Star Rating Program statin measures

SUPD and SPC

This quick reference tool contains a summary of facts about the two statin use measures in the Star Rating Program.

	Statin Use in Persons with Diabetes (SUPD) PQA™	Statin Therapy for Patients with Cardiovascular Disease (SPC) HEDIS*
Description	Percentage of Medicare Part D beneficiaries **40–75** years old dispensed medications for diabetes who receive **any** statin medication	Percentage of **males 21–75** years old and **females 40–75** years old who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one **high- or moderate-intensity statin** medication
Weight	1x	1x
Calculation (numerator/ denominator)	**Numerator:** Number of patients in the denominator who received **any statin** medication fill during the current measurement year **Denominator:** Number of patients 40–75 years old with at least two⁺ diabetes medication fills, **with two separate fill dates,** during the current measurement year	**Numerator:** Number of patients who had at least one dispensing event for a **high- or moderate-intensity statin** medication during the current measurement year **Denominator:** Number of patients who meet age criteria and event or diagnosis criteria: • **Event (during prior year):** – Myocardial infarction (MI) *when discharged from inpatient setting* – Coronary artery bypass grafting (CABG) – Percutaneous coronary intervention (PCI) – Any other revascularization • **Diagnosis (during prior and current year):** – At least one acute inpatient or outpatient visit with ischemic vascular disease (IVD) diagnosis (includes telephonic and virtual visits)

| **Exclusions and common ICD-10-CM code(s)** | **Patients in hospice care** – *N/A—please use Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS), SNOMED CT or UBREV codes* **Patients with a diagnosis of end-stage renal disease (ESRD)** – *I12.0, I13.11, I13.2, N18.5, N18.6, N19, Z99.2* **Patients with rhabdomyolysis or myopathy** – *G72.0, G72.89, G72.9, M60.80, M60.819, M60.829, M60.839, M60.849, M60.859, M60.869, M60.879, M60.9, M62.82* *(Note: 2023 Change – T46.6X5A, adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter removed as an exclusion.)* Patients who are: – **Pregnant[∞]** ○ *O00.101, O00.102, O00.109, O00.111, O00.112, O00.119, O00.201, O00.202, O00.209* – **Lactating** ○ *O91.03, O91.13, O91.23, O92.03, O92.13, O92.5, O92.70, O92.79, Z39.1* – **Dispensed clomiphene (Clomid) medication** ○ *N/A—capture via pharmacy claims* **Patients with cirrhosis** – *K70.30, K70.31, K71.7, K74.3, K74.4, K74.5, K74.60, K74.69* **Patients with prediabetes** – *R73.03, R73.09* **Patients with polycystic ovary syndrome (PCOS)** – *E28.2* | **Patients in hospice, using hospice or receiving palliative care** ○ *N/A—please use CPT, HCPCS, SNOMED CT or UBREV codes* Patients 66–75 years old who: – **Live long-term in an institutional setting** or are enrolled in an **Institutional Special Needs Plan (I-SNP)** and/or – **Have frailty and advanced illness[∞]** ○ *A81.00, C25.0, C71.0, C71.04, C77.0, C78.00, C79.00, C91.00, C92.00, C93.00, C94.30, F01.50, F02.80, F03.90, F04, F10.27, G10, G20, G30.0, G31.01, G35, I09.81, I11.0, I12.0, I13.0. I50.1, J43.0, J68.4, J84.10, J96.10, J98.2, K70.10, K74.0, N18.5, L89.000, M62.50, W01.0XXA, W06.XXXA, W07.XXXA, W08.XXXA, W10.0XXA, W18.00XA, W19.XXXA, Y92.199, Z59.3, Z73.6, Z74.01, Z91.81, Z99.11, R26.0, R41.81, R53.81, R54, R62.7, R63.4, R64* *(Note: CPT, HCPCS or SNOWMED CT codes also can be used)* Patients with the following diagnoses or services in the current or prior measurement year for: – **Pregnancy[∞]** ○ *O00.101, O00.102, O00.109, O00.111, O00.112, O00.119, O00.201, O00.202, O00.209* *(Note: SNOWMED CT codes also can be used)* – **In vitro fertilization (IVF)** ○ *N/A—use HCPCS or SNOMED CT codes* – **Dispensed clomiphene (Clomid) medication** ○ *N/A—capture via pharmacy claims* – **End-stage renal disease (ESRD) or dialysis** ○ *N18.5, N18.6, Z99.2, 585.5, 585.6, V45.11, 3E1M39Z, 5A1D00Z, 5A1D60Z, 5A1D70Z, 5A1D80Z, 5A1D90Z* *(Note: CPT, HCPCS or SNOWMED CT codes also can be used)* – **Cirrhosis** ○ *K70.30, K70.31, K71.7, K74.3, K74.4, K74.5, K74.60, K74.69, P78.81* *(Note: SNOWMED CT codes also can be used)* Patients with **myalgia, myositis, myopathy or rhabdomyolysis** during the current measurement year ○ *G72.0, G72.2, G72.9, M60.80, M60.811, M60.812, M60.819, M60.821, M60.822, M60.829, M60.831, M60.832, M60.839, M60.841, M60.842, M60.849, M60.851, M60.852, M60.859, M60.861, M60.862, M60.869, M60.871, M60.872, M60.879, M60.88, M60.89, M60.9, M62.82, M79.10, M79.11, M79.12, M79.18* |

		(Note: SNOWMED CT codes also can be used)
General trend	A higher rate of compliance is better	A higher rate of compliance is better

* HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).
† Index prescription start date for the diabetes medication must occur at least 90 days prior to the end of the measurement year.
∞ ICD-10 code list is not comprehensive. Please contact a Humana representative with any questions.
PQA – Pharmacy Quality Alliance
HEDIS – Healthcare Effectiveness Data and Information Set
ICD-10-CM created by the National Center for Health Statistics under authorization by the World Health Organization (WHO). WHO is the copyright holder.

NCQA Copyright Notice and Disclaimer

The HEDIS measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program. Reprinted with permission by NCQA. © 2023 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The full text of this notice and disclaimer is available at http://apps.humana.com/marketing/documents.asp?file=4274309.